PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside

Area of Science:

• Molecular Biology
• Cellular Signaling
• Oncology

Background:

• The Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a critical regulator of fundamental cellular processes.
• This pathway controls cell proliferation, growth, metabolism, and motility.
• Aberrant activation of PI3K/Akt/mTOR pathway genes is frequently observed in human cancers.

Purpose of the Study:

• To review recent advancements in targeting the PI3K/Akt/mTOR pathway for cancer treatment.
• To discuss the development and application of small molecule inhibitors in molecular targeted therapy.
• To highlight FDA-approved inhibitors and ongoing clinical evaluations.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of small molecule inhibitors targeting the PI3K/Akt/mTOR pathway.
• Examination of regulatory approvals and trial outcomes.

Main Results:

• Inhibition of the PI3K/Akt/mTOR pathway has demonstrated tumor regression in preclinical models.
• Numerous clinical trials have evaluated PI3K/Akt/mTOR inhibitors.
• Several inhibitors have received FDA approval based on demonstrated efficacy and safety.

Conclusions:

• Targeting the PI3K/Akt/mTOR pathway represents a significant strategy in molecular cancer therapy.
• Small molecule inhibitors are effective tools for this targeted approach.
• Continued research and clinical trials are essential for optimizing PI3K/Akt/mTOR-based cancer treatments.